Payment overview · 2025
General Payments
$155.42
8 reported records · 5 companies
Healthcare provider profile · identity verified
Daniel E Kosobucki, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, GA · NPI 1881775518
Verified facts
What the public records show
CMS Open Payments records show Daniel E Kosobucki, M.D. received $155.42 in general payments during 2025 across 8 reported records.
Novartis Pharmaceuticals Corporation accounted for 37.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $58.66 | 37.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.33 | 21.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.98 | 16.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.50 | 14.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.95 | 10.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $155.42 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $58.66 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 577 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 91 |
| Lisinopril | Lisinopril | 263 | 68 |
| Alprazolam | Alprazolam | 243 | 57 |
| Metformin Hcl | Metformin Hcl | 224 | 56 |
| Gabapentin | Gabapentin | 193 | 49 |
| Omeprazole | Omeprazole | 183 | 55 |
| Losartan Potassium | Losartan Potassium | 161 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 49 |
| Jardiance | Empagliflozin | 157 | 27 |
| Simvastatin | Simvastatin | 155 | 42 |
| Sertraline Hcl | Sertraline Hcl | 149 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 37 |
| Glimepiride | Glimepiride | 117 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 35 |
| Carvedilol | Carvedilol | 116 | 35 |
| Furosemide | Furosemide | 113 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 33 |
| Eliquis | Apixaban | 107 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 21 |
| Trazodone Hcl | Trazodone Hcl | 94 | 26 |
| Meloxicam | Meloxicam | 93 | 31 |
| Tramadol Hcl | Tramadol Hcl | 91 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 30 |
| Clonazepam | Clonazepam | 88 | 18 |
| Allopurinol | Allopurinol | 87 | 25 |
| Potassium Chloride | Potassium Chloride | 86 | 24 |
| Baclofen | Baclofen | 85 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 25 |
| Bupropion Xl | Bupropion Hcl | 72 | 19 |
| Nifedipine Er | Nifedipine | 66 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 22 |
| Ezetimibe | Ezetimibe | 63 | 15 |
| Ozempic | Semaglutide | 62 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 61 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 13 |
| Estradiol | Estradiol | 57 | 15 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 47 |
| Montelukast Sodium | Montelukast Sodium | 56 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 14 |
| Prednisone | Prednisone | 50 | 36 |
| Fenofibrate | Fenofibrate | 48 | 12 |
| Valsartan | Valsartan | 45 | 12 |
| Famotidine | Famotidine | 44 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Rybelsus | Semaglutide | 43 | 11 |
| Spironolactone | Spironolactone | 43 | 14 |
| Fluconazole | Fluconazole | 41 | 19 |
| Metformin Hcl Er | Metformin Hcl | 39 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 15 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 19 |
| Colchicine | Colchicine | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $155.42 · 8 records | Novartis Pharmaceuticals Corporation | ENTRESTO, LEQVIO, REXULTI, UBRELVY, VRAYLAR, Veozah, WaveWriter Alpha Prime 16 | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error